

UTILIZATION MANAGEMENT MEDICAL POLICY

POLICY: Oncology (Injectable – CAR-T) – Aucatzyl Utilization Management Medical Policy

- Aucatzyl® (obecabtagene autoleucel intravenous infusion – Autolus)

REVIEW DATE: 11/19/2025

OVERVIEW

Aucatzyl, a CD19-directed genetically modified autologous T cell immunotherapy, is indicated for the treatment of relapsed or refractory **B-cell precursor acute lymphoblast leukemia (ALL)** in adults.¹

Dosing Information

The recommended total dose of Aucatzyl is 410×10^6 CD19 chimeric antigen receptor (CAR)-positive viable T cells.¹ The dose is split, based on the percentage of blasts in the bone marrow within 7 days of starting lymphodepleting chemotherapy, and administered on Days 1 and 10 (± 2 days). The specific dosing schedule of Aucatzyl based on the percentage of blasts in the bone marrow is summarized in Table 1.

Table 1. Aucatzyl Dosing Schedule Based on the Percentage of Blasts in the Bone Marrow.¹

	Day 1	Day 10 (± 2 days)
Bone marrow blasts > 20%	10×10^6 CAR-T cells	400×10^6 CAR-T cells
Bone marrow blasts \leq 20%	100×10^6 CAR-T cells	310×10^6 CAR-T cells

CAR – Chimeric antigen receptor.

Guidelines

The National Comprehensive Cancer Network ALL (version 2.2025 – June 27, 2025) guidelines recommend Aucatzyl for the treatment of relapsed or refractory Philadelphia chromosome negative B-cell ALL as a “Preferred Regimen” (category 2A) and Philadelphia chromosome positive B-cell ALL following treatment with a tyrosine kinase inhibitor as an “Other Recommended Regimen” (category 2A).^{2,3}

Safety

Aucatzyl has a Boxed Warning concerning cytokine release syndrome, neurologic toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and secondary hematological malignancies.¹

POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Aucatzyl. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Because of the specialized skills required for evaluation and diagnosis of patients treated with Aucatzyl as well as the monitoring required for adverse events and long-term efficacy, approval requires Aucatzyl to be prescribed by or in consultation with a physician who specializes in the condition being treated. The approval duration is 6 months to allow for an adequate time frame to prepare and administer 1 dose of therapy.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Aucatzyl is recommended in those who meet the following criteria:

11/19/2025

© 2025. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

FDA-Approved Indication

- 1. Acute Lymphoblastic Leukemia.** Approve a single dose if the patient meets ALL of the following (A, B, C, D, E, and F):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has B-cell precursor disease; AND
 - C) Patient has relapsed or refractory disease; AND
 - D) Patient received or plans to receive lymphodepleting chemotherapy prior to infusion of Aucatzyl; AND
 - E) Patient has not been previously treated with CAR-T therapy; AND

Note: Examples of CAR-T therapy include Aucatzyl, Tecartus (brexucabtagene autoleucl intravenous infusion), Breyanzi (lisocabtagene maraleucl intravenous infusion), Kymriah (tisagenlecleucl intravenous infusion), Yescarta (axicabtagene intravenous infusion) and Abecma (idecabtagene vicleucl intravenous infusion).

 - F) The medication is prescribed by or in consultation with an oncologist.

Dosing. Approve the following dosing regimen (A and B):

- A) Administer a total dose of 410×10^6 CAR-T cells by intravenous infusion; AND
- B) The dose is split and administered on Days 1 and 10 (± 2 days).

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Aucatzyl is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Aucatzyl® intravenous infusion [prescribing information]. Gaithersburg, MD: Autolus; August 2025.
2. The NCCN Drugs and Biologics Compendium. © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on November 16, 2025. Search term: obecabtagene.
3. The NCCN Acute Lymphoblastic Leukemia Clinical Practice Guidelines in Oncology (version 2.2025 – June 27, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on November 16, 2025.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	11/20/2024
Update	12/27/2024: No criteria changes. Updated the Guideline section of the policy with National Comprehensive Cancer Network recommendations for Aucatzyl.	N/A
Annual Revision	No criteria changes.	11/19/2025